Gjata B, Hannoun C, Boulouis H J, Neway T, Pilet C
Institut d'Immunologie Animale et Comparée, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.
C R Acad Sci III. 1994 Mar;317(3):257-63.
Mice injected intraperitoneally with 2.5 or 25 mg/kg of pGPL-Mc, before, during or after the administration of a monovalent inactivated influenza vaccine (8 IU of A/New Jersey/X53), exhibited significantly very high haemagglutination inhibition (HI) antibody titers (up to 8 fold) as compared to vaccine controls. Treatment with pGPL-Mc has increased the protective effect of the vaccine by completely abolishing, in certain treatment groups, the onset of symptoms of disease and mortality after a lethal challenge with 5 LD50 of A/PR/8/34 virus, 60 days after the first vaccination. Moreover, the development of visible pulmonary lesions significantly decreased in surviving vaccinated mice treated with 25 mg/kg of pGPL-Mc on day D0. These results suggest that pGPL-Mc is a potent adjuvant to the immunogenic and protective effect of inactivated influenza vaccines.
在接种单价灭活流感疫苗（8个国际单位的A/新泽西/X53）之前、期间或之后，腹腔注射2.5或25毫克/千克pGPL-Mc的小鼠，与疫苗对照组相比，表现出显著非常高的血凝抑制（HI）抗体滴度（高达8倍）。用pGPL-Mc治疗提高了疫苗的保护效果，在某些治疗组中，首次接种疫苗60天后，用5个半数致死剂量的A/PR/8/34病毒进行致死性攻击后，完全消除了疾病症状的出现和死亡率。此外，在第0天用25毫克/千克pGPL-Mc治疗的存活接种小鼠中，可见肺部病变的发展显著减少。这些结果表明，pGPL-Mc是灭活流感疫苗免疫原性和保护作用的有效佐剂。
